Submit manuscript...
eISSN: 2473-0815

Endocrinology & Metabolism International Journal

Research Article Special Issue Thyroid Research

“Thyroid disfunction induced by sunitinb treatmentin oncological patients”

Laura Rizza,1 Francesca Rota,1 Paola Di Giacinto,1 Andrea Isidori,2 Andrea Lenzi,2 Paolo Zuppi,1 Roberto Baldelli1

1Unit of Endocrinology, San Camillo Forlanini Hospital, Rome
2Department of Experimental Medicine, “Sapienza” University of Rome, Italy

Correspondence: Roberto Baldelli, Unit of Endocrinology, San Camillo Forlanini Hospital, Rome, Italy

Received: April 11, 2017 | Published: November 15, 2018

Citation: Rizza L, Rota F, Innocenti A, et al. “Thyroid disfunction induced by sunitinb treatment in oncological patients”. Endocrinol Metab Int J. 2018;6(6):374-376. DOI: 10.15406/emij.2018.06.00214

Download PDF


Sunitinb (SUN) belongs to a new class of multi targeted tyrosine kinase inhibitors (TKIs) used in treatment of metastatic renal cell carcinoma, gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. Although generally well tolerated with favourable safety profile, SUN has distinct side effects that differ from the standard chemotherapy and require monitoring and management. Hypothyroidism is one of the most important adverse events induced by SUN. It is usually subclinical and rarely severe, with variable incidence in according to the different studies. The potential mechanisms involved in thyroid dysfunction are not fully understood: the best known hypotheses about the pathogenesis of SUN-induced hypothyroidism are a progressive depletion of the thyroid reserve through inhibition of thyroid peroxidises activity, a decrease in the iodine uptake ability, a capillary regression in the thyroid gland, a possible autoimmune damage. Generally, SUN-induced hypothyroidism does not require discontinuation of cancer therapy but only needs the thyroid replacement therapy. The occurrence of SUN-induced hypothyroidism appears associated with successful treatment in term of survival of Oncological patients but more clinical investigations are necessary to validate this correlation.


The tyrosine kinase inhibitors (TKIs) are enzymatic receptor proteins designed to block the ATP-binding site in tyrosine kinases involved in several cellular processes such as, proliferation, differentiation, survival, migration and angiogenesis. Although their mechanism of action is the same, they differ in the spectrum of targeted kinases, pharmacokinetics and specific adverse events.1 TKIs have different toxicity than conventional chemotherapy agents.2 The side effects are rarely life-threatening but may reduce quality of life.3 Many of the most common adverse effects occur during the treatment with all the TKIs, while others are more specific to individual agents.4


Sunitinib (SUN) is an oral, small-molecule TKI that is structurally similar to adenosine triphosphate. It has been approved by the Food and Drug Administration for patients with metastatic renal cell cancer (mRCC), imatinib-resistant gastrointestinal stromal tumour and advanced pancreatic neuroendocrine tumour.5–7 SUN inhibits cellular signaling by targeting multiple receptor tyrosine kinases, including all receptors for the three is forms of VEGF, PDGF, FMS-like tyrosine kinase-3 and stem cell factor receptor. SUN also binds RET CD114 and CD135 receptors.8–13 The simultaneous inhibition of these targets reduces tumour vascularization and triggers cancer cell apoptosis, thus resulting in tumour shrinkage. The recommended dose of SUN is 50 mg oral dose taken once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off. Dose interruption and/or dose modification in 12.5 mg increments or decrements is recommended based on individual safety and tolerability. The daily dose should not exceed 75 mg and not drop below 25 mg.

SUN is generally well tolerated and the frequency of common toxicity criteria (CTC) grade 3 or 4 is low (≤10%). However, some distinct side effects require monitoring and treatment. The most common adverse events associated with SUN therapy are fatigue, diarrhoea, nausea, anorexia, hypertension, a yellow skin discoloration, hand-foot skin reaction, hypothyroidism, stomatitis, altered taste and constipation.2,14,15 The side effects can be managed through supportive care, dose interruption or reduction.

Sunitinib and thyroid dysfunction

Biochemical and clinical hypothyroidism is commonly reported in SUN treated patients.16–18 Its prevalence in the various studies varies from 50-85% in retrospective trials16,19 to 36-46% in prospective and observational studies.20–27 This discrepancy is probably due to differences in the study design, sample size, definition of hypothyroidism and previous use of cytokine therapy.22

Hypothyroidism induced by SUN is usually subclinical (TSH elevation alone with normal FT4 levels) or overt (TSH elevation and low FT4) but rarely severe.21 In general, thyroid dysfunction arises from 12 to 50 weeks after starting SUN and is correlated with treatment duration.28 The mechanism of SUN-associated hypothyroidism is unclear and the course of the disease is not fully understood.22,24 Several underlying mechanisms might be involved: reduced synthesis of thyroid hormones through inhibition of thyroid peroxidise (TPO) activity and progressive depletion of the thyroid reserve;19 inhibition of iodine thyroidal uptake;21 glandular atrophy induced by TKIs through the inhibition of vascularisation (direct action on VEGFR and/or PDGFR);29,30 possible autoimmune damage that causes lymphocytic Thyroiditis in patients receiving SUN.22,31 As regards thyroid ultrasound assessment, the majority of literature demonstrated a progressive reduction in thyroid size, mainly after three months of SUN treatment, regardless of the SUN phase (ON/OFF). This was combined with marked hypoechogenicity and reduced parenchyma perfusion, probably as a result of SUN’s anti-angiogenic effect.32-34

Hypothyroidism and cancer’s outcome

SUN-induced hypothyroidism has also been proposed as a possible predictive factor for the outcome of the cancer treatment, although the conclusions are still unclear.23–27,35,36 A preliminary study of SUN treatment for mRCC suggested that hypothyroid patients had a significantly longer PFS than euthyroid patients.22 Schmidinger prospectively studied the correlation between the onset of hypothyroidism and the rate of disease remission, discovering a higher overall response rate in hypothyroid than in euthyroid patients (ORR: 28.3% vs. 3.3%; p<0.001).24 Recently, Buda-Nowak showed that patients who had developed hypothyroidism had better median progression free survival to patients with normal thyroid function 28,3 months [95% (CI) 20.4–36.2 months] versus 9.8 months (6.4–13.1 months), recommending, during SUN treatment, the thyroid evaluation regularly.37 In contrast, in a prospective observational multicentre study, Sabatier found that thyroid dysfunction did not increase survival in SUN-treated patients with mRCC; after six months of SUN, 53% of patients developed hypothyroidism, with a median PFS of 18.9 months compared to 15.9 for the euthyroid group.27 More clinical investigations are necessary to explain the correlation between thyroid function and progression free survival/overall survival and the possible clinical usefulness of TSH as potential tumour biomarker in SUN-treated patients.



Conflict of interest

The authors declare no conflicts of interest.


  1. Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470–481.
  2. Di Lorenzo G1, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59(4):526–540.
  3. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6(4):219–228.
  4. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104(2):93–113.
  5. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302.
  6. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.
  7. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501–513.
  8. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337.
  9. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471–478.
  10. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597–3605.
  11. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109.
  12. Sulkes A. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. Isr Med Assoc J. 2010;12(10):628–632.
  13. Aparicio-Gallego G, Blanco M, Figueroa A, et al. New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther. 2011;10(12):2215–2223.
  14. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–1338.
  15. Fratto ME, Imperatori M, Vincenzi B, et al. New perspectives: role of Sunitinib in breast cancer. Clin Ter. 2011;162(3):251–257.
  16. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81–83.
  17. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008;19(2):265–268.
  18. Miyake H, Kurahashi T, Yamanaka K, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol. 2010;28(5):515–519.
  19. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17(4):351–355.
  20. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145(9):660–664.
  21. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92(9):3531–3534.
  22. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99(3):448–454.
  23. Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29(6):807–813.
  24. Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse. Cancer. 2011;117(3):534–544.
  25. Shinohara N, Takahashi M, Kamishima T, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 2011;104(2):241–247.
  26. Baldazzi V, Tassi R, Lapini A, et al. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol. 2012;30(5):704–710.
  27. Sabatier R, Eymard JC, Walz J, et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma. Ann Oncol. 2012;23(3):714–721.
  28. Vetter ML, Kaul S, Iqbal N. Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target. Endocr Pract. 2008;14(5):618–624.
  29. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290(2):H547–H559.
  30. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290(2):H560–H576.
  31. Alexandrescu DT, Popoveniuc G, Farzanmehr H, et al. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid. 2008;18(7):809–812.
  32. Pani F, Atzori F, Baghino G, et al. Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved? Thyroid. 2015;25(11):1255–1261.
  33. Rogiers A, Wolter P, Op de BK, et al. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction. Thyroid. 2010;20(3):317–322.
  34. Makita N, Miyakawa M, Fujita T, et al. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid. 2010;20(3):323–326.
  35. Garfield DH, Hercbergs A, Davis PJ. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(12):975–976.
  36. Bozkurt O, Karaca H, Hacibekiroglu I, et al. Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients. J Chemother. 2016;28(3):230–234.
  37. Buda-Nowak A, Kucharz J, Dumnicka P, et al. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients. Med Oncol. 2017;34(4):68.
Creative Commons Attribution License

©2018 Rizza, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.